[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3615023T3 - LIPOYL-GLU-ALA FOR THE TREATMENT OF NEURODEGENERATED DAMAGE CAUSED BY TRAUMATIC BRAIN INJURY - Google Patents

LIPOYL-GLU-ALA FOR THE TREATMENT OF NEURODEGENERATED DAMAGE CAUSED BY TRAUMATIC BRAIN INJURY Download PDF

Info

Publication number
DK3615023T3
DK3615023T3 DK18724073.4T DK18724073T DK3615023T3 DK 3615023 T3 DK3615023 T3 DK 3615023T3 DK 18724073 T DK18724073 T DK 18724073T DK 3615023 T3 DK3615023 T3 DK 3615023T3
Authority
DK
Denmark
Prior art keywords
neurodegenerated
lipoyl
glu
ala
treatment
Prior art date
Application number
DK18724073.4T
Other languages
Danish (da)
Inventor
Alexander Baguisi
Reinier Beeuwkes
Ralph Casale
David A Dewahl Jr
Steven A Kates
Alan S Lader
Original Assignee
Ischemix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ischemix Llc filed Critical Ischemix Llc
Application granted granted Critical
Publication of DK3615023T3 publication Critical patent/DK3615023T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK18724073.4T 2017-04-25 2018-04-25 LIPOYL-GLU-ALA FOR THE TREATMENT OF NEURODEGENERATED DAMAGE CAUSED BY TRAUMATIC BRAIN INJURY DK3615023T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762489735P 2017-04-25 2017-04-25
PCT/US2018/029372 WO2018200680A1 (en) 2017-04-25 2018-04-25 Compositions and methods for treating traumatic brain injury

Publications (1)

Publication Number Publication Date
DK3615023T3 true DK3615023T3 (en) 2023-09-25

Family

ID=62148517

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18724073.4T DK3615023T3 (en) 2017-04-25 2018-04-25 LIPOYL-GLU-ALA FOR THE TREATMENT OF NEURODEGENERATED DAMAGE CAUSED BY TRAUMATIC BRAIN INJURY

Country Status (9)

Country Link
US (3) US10744115B2 (en)
EP (2) EP4282411A1 (en)
JP (2) JP7203756B2 (en)
CN (1) CN110913851B (en)
AU (2) AU2018258158A1 (en)
CA (1) CA3061203A1 (en)
DK (1) DK3615023T3 (en)
ES (1) ES2952834T3 (en)
WO (1) WO2018200680A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110913851B (en) * 2017-04-25 2023-08-25 伊斯切米克斯公司 Compositions and methods for treating traumatic brain injury
US20240124520A1 (en) * 2019-10-16 2024-04-18 The Board Of Trustees Of The Leland Stanford Junior University N-acylated histidine dipeptides as anticancer agents
CN116199666A (en) * 2023-03-07 2023-06-02 中国药科大学 Amphiphilic compounds and pharmaceutical compositions thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1047991B (en) 1957-11-20 1958-12-31 Nordmark Werke Gmbh Process for the production of chemically stable, non-toxic, sterile injection solutions from thioctic acid
US3875207A (en) 1967-01-25 1975-04-01 Ciba Geigy Corp Process for the temporary protection of amino groups in peptide syntheses
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
CA1219824A (en) 1981-04-17 1987-03-31 David C. Ward Modified nucleotides and methods of preparing and using same
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5288706A (en) 1987-12-25 1994-02-22 Mitsui Toatsu Chemicals, Incorporated Medicament for prevention and remedy of diseases of the pancreas and others
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
FR2653334B1 (en) 1989-10-19 1991-12-20 Erphar Ste Civile COSMETIC TANNING PREPARATION.
ES2115589T3 (en) 1989-11-09 1998-07-01 Asta Medica Ag MEDICATION CONTAINING R-ALPHA-LIPONIC ACID OR S-ALPHA-LIPONIC ACID AS AN ACTIVE SUBSTANCE.
DE4000397A1 (en) 1990-01-09 1991-07-11 Hoechst Ag LIPIDSELECTIVE ANTIOXIDANTS AND THEIR PREPARATION AND USE
ATE202490T1 (en) 1992-04-24 2001-07-15 Biocompatibles Ltd METHOD FOR REDUCING MICROORGANISM LIABILITY
DE4235912C2 (en) 1992-10-23 2002-12-05 Viatris Gmbh Process for the preparation of crystalline thioctic acid and its use
DE4433764A1 (en) 1994-09-22 1996-03-28 Asta Medica Ag Dosage forms containing alpha-lipoic acid, solid salts of R-thioctic acid with improved release and bioavailability
EP0838472A4 (en) 1995-06-21 2000-02-02 Asahi Chemical Ind Peptides binding to low-density lipoproteins
JPH0990542A (en) 1995-09-28 1997-04-04 Konica Corp Silver halide photographic ensitive material
FR2741075B1 (en) 1995-11-15 1998-01-30 Rech De Pathologie Appliquee S PEPTIDE CONJUGATES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THEM
WO1998010090A1 (en) 1996-09-06 1998-03-12 St. Elizabeth's Medical Center Of Boston, Inc. Gata-6 transcription factor: compositions and methods
IL123887A0 (en) 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
JPH117099A (en) 1997-06-13 1999-01-12 Fuji Photo Film Co Ltd Silver halide photographic sensitive material
US6090842A (en) 1998-03-10 2000-07-18 The Regents Of The University Of California Lipoic acid analogs
DE19834608A1 (en) 1998-07-31 2000-02-03 Basf Ag Crystal modification of lipoic acid
JP2000169371A (en) 1998-10-02 2000-06-20 Sankyo Co Ltd Medicament containing dithiolane derivative
EP1133317A1 (en) 1998-11-26 2001-09-19 Pentapharm AG Transport system conjugate
US7214658B2 (en) 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
WO2001009118A2 (en) 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2001036454A1 (en) 1999-11-18 2001-05-25 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
WO2001080851A1 (en) 2000-04-21 2001-11-01 United States Army Medical Research And Materiel Command Method of treating, preventing or inhibiting central nervous system injuries and diseases
JP2002189271A (en) 2000-12-21 2002-07-05 Fuji Photo Film Co Ltd Silver halide photosensitive material and processing method for the same
ATE446949T1 (en) 2001-03-19 2009-11-15 Senju Pharma Co NEW A-LIPOMIC ACID DERIVATIVE AND USE THEREOF
US20050130881A1 (en) 2001-05-25 2005-06-16 Shashoua Victor E. Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
JP4259813B2 (en) 2001-05-29 2009-04-30 千寿製薬株式会社 Method for stabilizing α-lipoyl amino acid and aqueous liquid preparation containing stabilized α-lipoyl amino acid
DE10163836A1 (en) 2001-12-22 2003-07-10 Friz Biochem Gmbh Multifunctional reagent for the synthesis of thiol modified oligomers
WO2003055853A1 (en) 2001-12-26 2003-07-10 Nippon Soda Co., Ltd. Electron-accepting compounds capable of forming self-assembled monolayers
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
AU2003219880A1 (en) 2002-02-22 2003-09-09 Albany College Of Pharmacy Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease
JP2003286168A (en) 2002-03-28 2003-10-07 Senju Pharmaceut Co Ltd SKIN CARE PREPARATION CONTAINING alpha-LIPOYL AMINO ACID
JP4376540B2 (en) 2002-05-31 2009-12-02 アイバイツ株式会社 Metal surface modifiers and new sulfur-containing compounds
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
DE60229003D1 (en) 2002-07-29 2008-10-30 Nanodel Technologies Gmbh NANOPARTICLES FOR DNA DELIVERY TO A TARGET ORGAN
CN100556546C (en) 2003-02-13 2009-11-04 贝克顿·迪金森公司 In blood collection procedure, remove the device and the use thereof of composition
EP1454627A1 (en) 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
US20040204340A1 (en) 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
US7202270B2 (en) 2003-06-20 2007-04-10 Sami Labs Limited Convenient stable non-hygroscopic crystalline solid forms of racemic and chiral LA-plus salts: process for their manufacture and uses
US8088935B2 (en) 2003-12-23 2012-01-03 Ironwood Pharmaceuticals, Inc. Compounds and methods for the treatment of asthma
EP1726596A4 (en) 2004-02-18 2009-08-26 Japan Science & Tech Agency Sugar chain ligand composite and method of analyzing protein with the ligand composite
JP2006022066A (en) 2004-07-09 2006-01-26 Shiseido Co Ltd Polymerization inhibitor and instant-type melanogenesis preventive skin care preparation
WO2006101909A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Combination therapy for treating or preventing diseases
WO2006101910A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Peptide compounds and methods of using peptide compounds to treat conditions affecting the cardiac, pulmonary, and nervous systems
JP2008174453A (en) 2005-04-28 2008-07-31 Iwaki Kk Therapeutic agent for scalp alopecia
US8507439B2 (en) * 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
JP4951226B2 (en) 2005-09-08 2012-06-13 立山化成株式会社 Method for producing α-lipoic acid alkali salt
EP1940419A2 (en) 2005-09-09 2008-07-09 Oregon Health and Science University Neuroprotectants
ATE464890T1 (en) 2006-03-28 2010-05-15 Epitech Group Srl A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PATHOLOGIES CAUSED BY THE GENERAL IMMUNE RESPONSE
US20080051691A1 (en) 2006-08-28 2008-02-28 Wyeth Implantable shunt or catheter enabling gradual delivery of therapeutic agents
EP2364304A1 (en) 2008-11-07 2011-09-14 ISTITUTO BIOCHIMICO NAZIONALE SAVIO s.r.l. Alpha-lipoic acid derivatives and their use in drug preparation
US7928067B2 (en) * 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
US8080674B2 (en) 2009-06-12 2011-12-20 Ampac Fine Chemicals Llc. Preparation of polymer-free R-(+)-α-lipoic acid magnesium salt
EP4082542A1 (en) 2009-06-15 2022-11-02 Encore Health, LLC Dithiol compounds, derivatives, and uses therefor
ES2524706T3 (en) 2009-06-15 2014-12-11 Encore Health, Llc Choline esters
IT1397154B1 (en) 2010-01-04 2013-01-04 Ghelardini EFFECTIVE COMPOUNDS BOTH ANALGESIC AND ANTIPERALGESIC.
EP2640423B1 (en) 2010-11-18 2017-07-26 Ischemix LLC Lipoyl compounds and their use for treating ischemic injury
WO2015174948A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations comprising lipoyl compounds
US20150329519A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations Comprising Lipoyl Compounds
CN110913851B (en) * 2017-04-25 2023-08-25 伊斯切米克斯公司 Compositions and methods for treating traumatic brain injury

Also Published As

Publication number Publication date
JP7203756B2 (en) 2023-01-13
CA3061203A1 (en) 2018-11-01
EP3615023A1 (en) 2020-03-04
CN110913851B (en) 2023-08-25
EP4282411A1 (en) 2023-11-29
US20220280477A1 (en) 2022-09-08
JP2020517731A (en) 2020-06-18
US10744115B2 (en) 2020-08-18
WO2018200680A1 (en) 2018-11-01
ES2952834T3 (en) 2023-11-06
EP3615023B1 (en) 2023-06-21
AU2024202147A1 (en) 2024-05-02
AU2018258158A1 (en) 2019-11-21
JP2023030158A (en) 2023-03-07
US20180303796A1 (en) 2018-10-25
CN110913851A (en) 2020-03-24
US20200352904A1 (en) 2020-11-12
US11213509B2 (en) 2022-01-04

Similar Documents

Publication Publication Date Title
DK3570844T3 (en) AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS
DK3261640T3 (en) 5HT AGONISTS FOR THE TREATMENT OF EPILEPSY DISORDERS
DK3349758T3 (en) PROCEDURES FOR THE TREATMENT OF ARENAVIRIDAE VIRUS INFECTIONS
DK3185876T3 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
DK3125875T3 (en) INHALABLE RAPAMYCINFORMULATION FOR THE TREATMENT OF AGING-RELATED CONDITIONS
DK3439635T3 (en) FORMULATIONS FOR THE TREATMENT OF FIXED TUMOR
DK3240612T3 (en) PROCEDURES FOR THE TREATMENT OF RHINTH DISEASES
DK3148529T3 (en) COMPOUNDS FOR THE TREATMENT OF BRAIN CANCER
DK3390390T3 (en) Bipyrazolyl derivatives suitable for the treatment of autoimmune diseases
DK3362066T3 (en) COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES
DK3288577T3 (en) ADIPONECTIN PEPTIDOMIMETICS FOR THE TREATMENT OF EYE DISORDERS
DK3169328T3 (en) QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATION DISEASES
DK3524255T3 (en) COMPOSITION FOR THE TREATMENT OF ACNE
DK3265087T3 (en) PROCEDURE FOR TRADIPITANT TREATMENT
DK3157534T3 (en) ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS
BR112016022976A2 (en) METHODS FOR THE TREATMENT OF HCV
DK3307267T3 (en) TREATMENT OF MULTIPLE SHELLOSIS
DK3261661T3 (en) MENOTROPIN FOR THE TREATMENT OF INFERTILITY
DK3430143T3 (en) Inhibitors of SRSF1 for the treatment of neurodegenerative diseases
DK3439661T3 (en) PROCEDURES FOR THE TREATMENT OF EYE DISORDERS
DK3210973T3 (en) HETEROARYL COMPOUNDS FOR THE TREATMENT OF Ophthalmic Diseases
DK3192524T3 (en) HGF PREPARATION SUITABLE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
DK3256466T3 (en) 1-HETEROCYCLYL-ISOCHROMANYL COMPOUNDS AND ANALOGS FOR THE TREATMENT OF CNS DISORDERS
DK3416580T3 (en) Device for irradiation of the skin
DK3302573T3 (en) COMPOSITION FOR THE TREATMENT OF BRAIN LESSIONS